Breast cancer: bisphosphonate therapy for metastatic bone disease.
about
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical PracticeJaw osteonecrosis management around a dental implant inserted 2 years before starting treatment with zoledronic acid.Gorham-Stout disease of the proximal fibula treated with radiotherapy and zoledronic acid.Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells.A member of the Ras oncogene family, RAP1A, mediates antileishmanial activity of monastrolInsights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer.Significance and impact of bisphosphonate-induced acute phase responses.Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women.Biphosphonates-related osteonecrosis of the jaw: Clinical and physiopathological considerations.Painful prosthesis: approaching the patient with persistent pain following total hip and knee arthroplasty.Optimal management of bone metastases in breast cancer patients.Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma.Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature.Denosumab for the management of bone disease in patients with solid tumors.Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection.Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen.
P2860
Q31150676-2C491C58-F12D-478F-B596-5D73C372E73EQ35667196-8F1E151E-74BE-4B3A-8266-6364E6C77398Q36009806-7491DCD8-7157-4D67-87A9-719787F1B1E6Q36207586-742E0289-771C-4692-A488-0CDCBCE42C97Q36643023-8855D342-5126-4E9E-B51F-9CDB8FBFF02BQ36762981-1F4DEBFD-1742-4003-878C-7072A54FCEADQ36950482-C0CB29A6-8885-4922-9129-B29F9103B575Q37018333-BFB380DF-74E5-42BB-BC32-8A0806FD32BBQ37192926-A3BBA140-9806-4B90-8689-0D94555040A0Q37230315-8BFCDD52-40F0-4579-A114-0E4138C44CABQ37230596-877FC892-2513-4D48-90B3-EC304DCCA8B3Q37355487-71354496-D8DA-49B9-8A2B-F43AC857EF25Q37409192-63EBB0C0-BAA9-4CB9-BC62-7086C4585D8BQ37708869-FF473540-1886-4E51-B696-D8E6C74D84B4Q37970800-016CAB26-0F58-4BBF-B2B1-DB43FD9999C3Q39801202-507E896D-0E91-4D93-AA81-D33BB8DAAA55Q39899122-CBB873C7-2D74-4C5D-9820-B2BB6CA83630
P2860
Breast cancer: bisphosphonate therapy for metastatic bone disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Breast cancer: bisphosphonate therapy for metastatic bone disease.
@ast
Breast cancer: bisphosphonate therapy for metastatic bone disease.
@en
type
label
Breast cancer: bisphosphonate therapy for metastatic bone disease.
@ast
Breast cancer: bisphosphonate therapy for metastatic bone disease.
@en
prefLabel
Breast cancer: bisphosphonate therapy for metastatic bone disease.
@ast
Breast cancer: bisphosphonate therapy for metastatic bone disease.
@en
P1476
Breast cancer: bisphosphonate therapy for metastatic bone disease.
@en
P2093
Jean-Jacques Body
P304
6258s-6263s
P356
10.1158/1078-0432.CCR-06-0840
P407
P433
P577
2006-10-01T00:00:00Z